인실리코 신약 개발 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The In-Silico Drug Discovery Market size is expected to reach USD 16.64 Billion in 2034 from USD 4.21 Billion (2025) growing at a CAGR of 16.51% during 2026-2034.

The Global In-Silico Drug Discovery Market is rapidly gaining momentum as pharmaceutical companies increasingly adopt computational methods to accelerate drug development. In-silico technologies use computer simulations, artificial intelligence, and advanced algorithms to identify potential drug candidates and predict their biological behavior. This approach significantly reduces the time and cost associated with traditional laboratory-based drug discovery processes.

One of the major growth drivers is the rising demand for faster and more efficient drug development, particularly in response to emerging diseases and complex medical conditions. Pharmaceutical and biotechnology companies are integrating artificial intelligence and machine learning into drug discovery workflows to enhance accuracy and efficiency. Additionally, increasing investments in bioinformatics and computational biology are further strengthening the market.

Looking ahead, the in-silico drug discovery market is expected to expand as digital technologies continue to transform pharmaceutical research. The growing use of big data analytics and cloud computing in drug development will enhance predictive modeling capabilities. As the healthcare industry seeks innovative solutions to accelerate therapeutic discoveries, the adoption of in-silico methods is likely to increase significantly.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Component

• Software
• Services

By Application

• Target Identification
• Target Validation
• Lead Discovery
• Lead Optimization
• Preclinical Testing
• Others

By End-User

• Pharmaceutical Companies
• Biotechnology Companies
• Contract Research Organizations
• Academic and Research Institutes
• Others

COMPANIES PROFILED

• Schrdinger Inc, Certara USA Inc, Charles River Laboratories International Inc, Evotec SE, BenevolentAI, Exscientia, Insilico Medicine, Atomwise Inc, Molecular Partners AG, Relay Therapeutics, XtalPi Inc, Numerate Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL IN-SILICO DRUG DISCOVERY MARKET: BY COMPONENT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Component
• 4.2. Software Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Services Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL IN-SILICO DRUG DISCOVERY MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Target Identification Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Target Validation Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Lead Discovery Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Lead Optimization Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Preclinical Testing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL IN-SILICO DRUG DISCOVERY MARKET: BY END-USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End-user
• 6.2. Pharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Biotechnology Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Contract Research Organizations Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Academic and Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL IN-SILICO DRUG DISCOVERY MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Component
  • 7.2.2 By Application
  • 7.2.3 By End-user
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Component
  • 7.3.2 By Application
  • 7.3.3 By End-user
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Component
  • 7.4.2 By Application
  • 7.4.3 By End-user
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Component
  • 7.5.2 By Application
  • 7.5.3 By End-user
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Component
  • 7.6.2 By Application
  • 7.6.3 By End-user
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL IN-SILICO DRUG DISCOVERY INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 SchrA¶Dinger Inc
  • 9.2.2 Certara USA Inc
  • 9.2.3 Charles River Laboratories International Inc
  • 9.2.4 Evotec SE
  • 9.2.5 BenevolentAI
  • 9.2.6 Exscientia
  • 9.2.7 Insilico Medicine
  • 9.2.8 Atomwise Inc
  • 9.2.9 Molecular Partners AG
  • 9.2.10 Relay Therapeutics
  • 9.2.11 XtalPi Inc
  • 9.2.12 Numerate Inc